A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

NCT Number	NCT07441278
Lead Sponsor	NS Pharma, Inc. Collaborators: Nippon Shinyaku Co., Ltd.
Conditions	Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Enrollment	177 participants
Start Date	2026-07-01
Primary Completion	2028-09-14 (estimated)
Study Completion	2028-12-14 (estimated)
Updated on ClinicalTrials.gov	2026-02-27